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Massive pulmonary thromboembolism (PTE) has an increased risk of mortality. 
Thrombolytic therapy is the accepted treatment. Reteplase, a variant of tissue 
plasminogen activator, has been used in acute myocardial infarction with 
acceptable safety and efficacy, but studies in massive PTE are rare. In this study 
we report five cases of successful treatment of massive PTE with reteplase. 
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INTRODUCTION 
Acute pulmonary thromboembolism (PTE) is a 
common and potentially lethal form of venous 
thromboembolism (VTE); PTE typically has a poor 
prognosis with a high mortality rate despite advances in 
diagnosis and therapy (1). Acute PTE has been classified 
into three groups: non-massive or low risk, submassive or 
moderate/intermediate risk, and massive or high risk. 
Patients presenting with persistent bradycardia, 
hypotension, syncope, cardiogenic shock, cardiac arrest, or 
respiratory failure define as massive PTE (2).  
These two groups (massive and submassive PTE) are at 
increased risk of mortality. The rapid reinstitution of 
sufficient pulmonary blood flow and right ventricular 
unloading is important to save the patient's life (3,4). 
Therapeutic methods in patients with massive PTE and 
hemodynamic collapse include thrombolytic agents, 
catheter-based thrombus fragmentation or aspiration, and 
surgical embolectomy (5). Thrombolytic therapy is widely 
used as a first line treatment with satisfactory results (6). 
Recent meta-analysis indicated that thrombolysis was 
associated with a significant reduction of all-cause 
mortality. However, following thrombolysis these patients 
are at risk of major bleeding and fatal or intracranial 
hemorrhage (7). Different thrombolytic agents have been 
introduced including alteplase, reteplase and tenecteplase. 
Reteplase is a variant of tissue plasminogen activator with 
an extended circulation time, lower fibrin affinity, and 
greater susceptibility to plasminogen inhibitors (8). 
Although the effectiveness of reteplase in acute 
myocardial infarction is known, few case reports and case 
studies have reported its utility in acute massive and sub-
massive PTE (9-12). Reteplase has been used in most 
centers to treat massive PTE, but it is not fully approved. In 
this study, we report a series of 5 cases with massive PTE 
treated with reteplase. 
 
MATERIALS AND METHODS 
In this retrospective study, five consecutive patients 
with massive PTE admitted to Imam Khomeini Hospital, 
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Ardabil, Iran, between September 2015 and April 2017 
were included. The patients with pulmonary embolism 
were confirmed by clinical symptoms and CT pulmonary 
angiography. Massive PTE was defined as sustained 
hypotension, pulselessness, or persistent profound 
bradycardia with signs or symptoms of shock in the 
presence of a newly developed thrombus in the common 
trunk, right or left main pulmonary artery (2).  
All these patients received reteplase 10 units IV bolus 
over 2 minutes followed 30 minutes later by a second 10 
unit IV bolus injection also administered over 2 minutes. 
Hospital records of all patients were reviewed for 
demographic data, predisposing factors, initial clinical 
presentation, diagnostic studies, hemodynamic status, 
thrombus location, and outcomes. All patients presented to 
our emergency department with hemodynamic instability 
and had tachycardia with S1Q3T3 in electrocardiogram, 
except case 2 that had normal ECG findings. 
Case 1 
The first patient was a 66-year-old female with history 
of seizure and bedridden for the last three months 
presenting with hypotension, chest pain and dyspnea. The 
symptoms begun in the last seven days. Primary 
echocardiography showed severe RV dysfunction with 
systolic pulmonary artery pressure (SPAP) of 75 mmHg. 
The patient received reteplase and during 7 days of 
admission had no major bleeding or any complications. 
SPAP had reduced to normal (25 mmHg) in a follow-up 
echocardiography. 
Case 2 
The second case was a 47-year-old male presenting 
with hypotension, chest pain and dyspnea that had lasted 
for three days. Doppler sonography showed acute deep 
vein thrombosis (DVT). Echocardiography showed severe 
RV dysfunction and RV enlargement with SPAP of 70 
mmHg which decreased following reteplase treatment 
(SPAP=20 mmHg). No complications were noted with 
reteplase treatment.  
Case 3 
The third case was a 64-year-old female who admitted 
with chest pain and non-ST elevation myocardial 
infarction; during admission she underwent percutaneous 
coronary intervention (PCI). Two days following PCI, the 
patient had persistent chest pain with hypotension and loss 
of consciousness, and was intubated. Imaging confirmed 
massive PTE and reteplase was administered. The patient 
had rectorrhagia in the first 24 hours and cerebellar 
hemorrhage 36 hours after reteplase administration. 
Patient was treated conservatively and was extubate in the 
next three days. Control brain imaging showed no further 
hemorrhage. Patient was discharged after 10 days with no 
further complications. 
Case 4 
The fourth patient was a 49-year-old male, a known 
case of COPD and ischemic heart disease with no 
predisposing factor, presenting with chest pain and vertigo 
in the last two days. RV enlargement and dysfunction and 
SPAP of 50 mmHg were reported in the primary 
echocardiography, which improved in the post treatment 
follow-up echocardiography with normal RV function. 
Patient had no complications and discharged after 6 days.  
Case 5 
The fifth patient was a 49-year-old male presenting 
with chest pain during the last two days with highest 
intensity at the time of visit. The patient had RV 
enlargement and dysfunction and SPAP of 60 mmHg in 
echocardiographic study, which improved to 30 mmHg 
following treatment. Three hours after reteplase 
administration, the patient had hemoptysis which was 
managed conservatively. The patient was discharged after 
2 days with no complications.  
After reteplase treatment, patients received heparin 
infusion and were discharged with warfarin. Patients were 
followed for three months and none had any complications 
during the follow-up period. All patients had follow-up 
echocardiography a week after discharge that indicated 
improved PAP and normal RV function. None of the 
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patients died during the hospital stay and follow-up 
period. 
 
DISCUSSION 
Massive PE is complicated by hemodynamic instability 
and RV dysfunction which has poor prognosis; therefore, 
early diagnosis, prompt risk stratification, and aggressive 
therapeutic strategies are necessary to reduce the mortality 
rate (1,2). Rapid restoration of the RV function and 
pulmonary blood flow will improve patient’s   survival 
(3,4).  
Thrombolytic therapy is the accepted treatment for 
patients with massive PTE; this therapy significantly 
improves pulmonary flow and RV function (13). Alteplase 
is the accepted tPA for the treatment. A few studies have 
also indicated possible efficacy of reteplase in massive PTE.  
We report 5 cases of massive PTE treated successfully 
with reteplase. All patients had improved 
echocardiographic parameters, stable hemodynamic and 
symptoms. Similarly, Liu and Wang (12) reported that 
reteplase can significantly relieve patients’ symptoms and 
improve hemodynamic state. Theron and Laidlow (10) also 
reported improvement in cardiovascular status following 
reteplase treatment. Tebbe et al. (11) showed significant 
changes in PAP and hemodynamic parameters following 
reteplase treatment. Reteplase efficacy in improving PAP 
and hemodynamic state is also shown in sub-massive    
PTE (12). 
Previous studies have reported that thrombolytic 
therapy is associated with risk of major bleeding in 13% 
and of intracranial or fatal hemorrhage in up to 3% of these 
patients (14-17). Among our patients, one case 
demonstrated rectorrhagia and cerebellar hemorrhage and 
one case had hemoptysis. Both patients were managed 
conservatively and bleeding was controlled.  
In the study of Liu and Wang (12), cerebral hemorrhage 
was seen in one case (5.5%). Zhao et al. (9) also reported 
one case of thrombolysis-related hemoptysis in their 
patients with sub-massive PTE. Theron and Laidlow (10) 
reported no bleeding in their study. Similarly, Tebbe et al. 
(11) reported no intracranial hemorrhage in their cases.  
Previous studies have shown that reteplase has similar 
risk of bleeding as other fibrin-specific thrombolytic agents 
(8,11); Tebbe et al. (11) noted that reteplase has similar 
safety and efficacy to alteplase in massive PTE.  
No mortality was reported among our cases. Similarly, 
Zhao et al. (9) reported no mortality in hospital and during 
follow-up. However, 5 cases (27.5%) died in the study of 
Liu and Wang (12). 
 
  CONCLUSION 
In conclusion, reteplase is effective in the treatment of 
patients with massive PTE and the benefits of reteplase are 
higher than its risk of bleeding.   
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